Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: the Pro-FEIBA Study

Trial Profile

Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: the Pro-FEIBA Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Factor VIII inhibitor bypassing fraction (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms PRO-FEIBA
  • Most Recent Events

    • 07 Nov 2012 Results of a quality-of-life analysis presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Nov 2012 Results of a cost-effectiveness analysis presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 21 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top